CO5690605A2 - Cci-779 para tratar linfoma de celulas del manto - Google Patents
Cci-779 para tratar linfoma de celulas del mantoInfo
- Publication number
- CO5690605A2 CO5690605A2 CO06052238A CO06052238A CO5690605A2 CO 5690605 A2 CO5690605 A2 CO 5690605A2 CO 06052238 A CO06052238 A CO 06052238A CO 06052238 A CO06052238 A CO 06052238A CO 5690605 A2 CO5690605 A2 CO 5690605A2
- Authority
- CO
- Colombia
- Prior art keywords
- cci
- cell lymphoma
- administered
- dose
- per week
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epoxy Compounds (AREA)
Abstract
1.- Un método de tratamiento o inhibición del linfoma de células del manto en un mamífero que necesita del mismo, caracterizado porque comprende proporcionar al mamífero una cantidad efectiva de un CCI-779.2.- El método de conformidad con la reivindicación 1, caracterizado por que el CCI-779 es administrado intravenosamente.3.- El método de conformidad con la reivindicación 1, caracterizado porque el CCI-779 es administrado semanalmente durante uno a doce meses.4.- El método de conformidad con la reivindicación 1, caracterizado porque el CCI-779 es administrado a una dosis de 10 a 100 mg por semana.5.- El método de conformidad con la reivindicación 1, caracterizado porque el CCI-779 es administrado intravenosamente a una dosis de 25 mg por semana.6.- El método de conformidad con la reivindicación 1, caracterizado porque el CCI-779 es administrado oralmente a una dosis de 100 mg a 250 mg por semana.7.- El uso de un CCI-779 en la preparación de un medicamento para tratar o inhibir el linfoma de las células del manto en un sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51732903P | 2003-11-04 | 2003-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5690605A2 true CO5690605A2 (es) | 2006-10-31 |
Family
ID=34590151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06052238A CO5690605A2 (es) | 2003-11-04 | 2006-05-31 | Cci-779 para tratar linfoma de celulas del manto |
Country Status (31)
Country | Link |
---|---|
US (2) | US20050113403A1 (es) |
EP (1) | EP1682131B9 (es) |
JP (1) | JP4856548B2 (es) |
KR (1) | KR101387988B1 (es) |
CN (1) | CN1901906B (es) |
AR (1) | AR046194A1 (es) |
AT (1) | ATE373477T1 (es) |
AU (1) | AU2004289213B2 (es) |
BR (1) | BRPI0415714A (es) |
CA (1) | CA2543665C (es) |
CO (1) | CO5690605A2 (es) |
CR (1) | CR8383A (es) |
DE (1) | DE602004009098T2 (es) |
DK (1) | DK1682131T3 (es) |
EC (1) | ECSP066600A (es) |
ES (1) | ES2291954T3 (es) |
GT (1) | GT200400224A (es) |
HK (1) | HK1088241A1 (es) |
IL (2) | IL175128A0 (es) |
MY (1) | MY136436A (es) |
NO (1) | NO20062271L (es) |
PA (1) | PA8616601A1 (es) |
PE (1) | PE20051000A1 (es) |
PL (1) | PL1682131T3 (es) |
PT (1) | PT1682131E (es) |
RU (1) | RU2358731C2 (es) |
SA (1) | SA04250375B1 (es) |
TW (1) | TW200517116A (es) |
UA (1) | UA83697C2 (es) |
WO (1) | WO2005046681A1 (es) |
ZA (1) | ZA200603533B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
WO2008066783A2 (en) * | 2006-11-27 | 2008-06-05 | Ariad Pharmaceuticals, Inc. | Therapeutic materials and methods |
CN104031122B (zh) * | 2014-06-23 | 2016-05-11 | 常州市肿瘤医院 | 有关Cyclin D蛋白抑制剂多肽及其应用 |
CN104017051B (zh) * | 2014-06-23 | 2016-08-17 | 深圳市华中生物药械有限公司 | 一种Cyclin D 蛋白抑制剂多肽及其应用 |
CN104004060B (zh) * | 2014-06-23 | 2016-04-13 | 重庆医科大学 | Cyclin D蛋白抑制剂多肽及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
ATE411321T1 (de) | 2000-09-19 | 2008-10-15 | Wyeth Corp | Wasserlösliche rapamycin-ester |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
EP1392286A2 (en) | 2001-06-01 | 2004-03-03 | Wyeth | Antineoplastic combinations |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
KR101131794B1 (ko) * | 2002-07-30 | 2012-03-30 | 와이어쓰 엘엘씨 | Cci-779 공용매 농축액, 비경구 cci-779 제형 및 비경구 cci-779 제형의 제조방법 |
EP1615640B1 (en) * | 2003-04-22 | 2007-01-24 | Wyeth | Antineoplastic combinations |
TW200524864A (en) | 2003-11-10 | 2005-08-01 | Wyeth Corp | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
-
2004
- 2004-10-25 AR ARP040103876A patent/AR046194A1/es unknown
- 2004-10-28 CA CA002543665A patent/CA2543665C/en active Active
- 2004-10-28 ES ES04796697T patent/ES2291954T3/es active Active
- 2004-10-28 AT AT04796697T patent/ATE373477T1/de not_active IP Right Cessation
- 2004-10-28 AU AU2004289213A patent/AU2004289213B2/en active Active
- 2004-10-28 CN CN2004800397222A patent/CN1901906B/zh active Active
- 2004-10-28 DK DK04796697T patent/DK1682131T3/da active
- 2004-10-28 EP EP04796697A patent/EP1682131B9/en active Active
- 2004-10-28 JP JP2006539565A patent/JP4856548B2/ja active Active
- 2004-10-28 WO PCT/US2004/035900 patent/WO2005046681A1/en active Application Filing
- 2004-10-28 KR KR1020067010939A patent/KR101387988B1/ko active IP Right Grant
- 2004-10-28 BR BRPI0415714-1A patent/BRPI0415714A/pt not_active Application Discontinuation
- 2004-10-28 RU RU2006119451/14A patent/RU2358731C2/ru active
- 2004-10-28 PL PL04796697T patent/PL1682131T3/pl unknown
- 2004-10-28 UA UAA200606167A patent/UA83697C2/ru unknown
- 2004-10-28 DE DE602004009098T patent/DE602004009098T2/de active Active
- 2004-10-28 PT PT04796697T patent/PT1682131E/pt unknown
- 2004-10-29 TW TW093132942A patent/TW200517116A/zh unknown
- 2004-11-01 MY MYPI20044512A patent/MY136436A/en unknown
- 2004-11-02 PE PE2004001059A patent/PE20051000A1/es not_active Application Discontinuation
- 2004-11-02 PA PA20048616601A patent/PA8616601A1/es unknown
- 2004-11-02 US US10/979,284 patent/US20050113403A1/en not_active Abandoned
- 2004-11-03 GT GT200400224A patent/GT200400224A/es unknown
- 2004-11-20 SA SA04250375A patent/SA04250375B1/ar unknown
-
2006
- 2006-04-24 IL IL175128A patent/IL175128A0/en unknown
- 2006-05-03 ZA ZA200603533A patent/ZA200603533B/en unknown
- 2006-05-05 CR CR8383A patent/CR8383A/es not_active Application Discontinuation
- 2006-05-19 NO NO20062271A patent/NO20062271L/no not_active Application Discontinuation
- 2006-05-31 CO CO06052238A patent/CO5690605A2/es not_active Application Discontinuation
- 2006-06-02 EC EC2006006600A patent/ECSP066600A/es unknown
- 2006-08-08 HK HK06108766A patent/HK1088241A1/xx not_active IP Right Cessation
-
2011
- 2011-04-01 US US13/078,272 patent/US8507518B2/en active Active
-
2012
- 2012-05-31 IL IL220080A patent/IL220080A0/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
AR020015A1 (es) | Composiciones de celecoxib | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
AR034746A1 (es) | Combinaciones para el tratamiento de trastornos inflamatorios | |
AR060089A1 (es) | Tratamiento del dolor | |
CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
CO5690605A2 (es) | Cci-779 para tratar linfoma de celulas del manto | |
BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
CO5590913A2 (es) | Terapia de combinacion antivirica | |
MY147391A (en) | Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds | |
BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
BR9909872A (pt) | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva | |
CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
BRPI0519036A2 (pt) | mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6 | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
AR047726A1 (es) | Metodos y reactivos para el tratamiento de trastornos inflamatorios | |
AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |